| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Addressing the shortage of cholera vaccines
|
Burki, Talha
|
|
|
22 |
12 |
p. 1674-1675
|
article
|
| 2 |
A new One Health Joint Action Plan
|
Jesudason, Timothy
|
|
|
22 |
12 |
p. 1673
|
article
|
| 3 |
Antibiotic prophylaxis for transperineal prostate biopsy? An unanswered question
|
Singhal, Udit
|
|
|
22 |
12 |
p. 1662
|
article
|
| 4 |
Antibiotic prophylaxis for transperineal prostate biopsy? An unanswered question – Authors' reply
|
Rud, Erik
|
|
|
22 |
12 |
p. 1663
|
article
|
| 5 |
A polio survivor's memoir
|
Bagcchi, Sanjeet
|
|
|
22 |
12 |
p. 1679
|
article
|
| 6 |
BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5
|
Tartof, Sara Y
|
|
|
22 |
12 |
p. 1663-1665
|
article
|
| 7 |
Correction to Lancet Infect Dis 2022; published online Sept 13. https://doi.org/10.1016/S1473-3099(22)00318-8
|
|
|
|
22 |
12 |
p. e348
|
article
|
| 8 |
COVID-19 sequelae: can long-term effects be predicted?
|
Gavriilaki, Eleni
|
|
|
22 |
12 |
p. 1651-1652
|
article
|
| 9 |
Early oral antiviral use in patients hospitalised with COVID-19
|
Zarębska-Michaluk, Dorota
|
|
|
22 |
12 |
p. 1650-1651
|
article
|
| 10 |
Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil
|
Florentino, Pilar T V
|
|
|
22 |
12 |
p. 1669-1670
|
article
|
| 11 |
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial
|
Datoo, Mehreen S
|
|
|
22 |
12 |
p. 1728-1736
|
article
|
| 12 |
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
|
Hardt, Karin
|
|
|
22 |
12 |
p. 1703-1715
|
article
|
| 13 |
Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial
|
Zhao, Fang-Hui
|
|
|
22 |
12 |
p. 1756-1768
|
article
|
| 14 |
Evaluating novel COVID-19 vaccines in the current chapter of the pandemic
|
GeurtsvanKessel, Corine H
|
|
|
22 |
12 |
p. 1652-1654
|
article
|
| 15 |
Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial
|
Lazarus, Rajeka
|
|
|
22 |
12 |
p. 1716-1727
|
article
|
| 16 |
Impact of COVID-19 measures in rural South Africa
|
Graham, Kitty
|
|
|
22 |
12 |
p. 1678
|
article
|
| 17 |
Infectious disease surveillance update
|
Zwizwai, Ruth
|
|
|
22 |
12 |
p. 1675
|
article
|
| 18 |
Isolated peritoneal involvement as a primary manifestation of cystic echinococcosis
|
Schwarz, Michael
|
|
|
22 |
12 |
p. 1769
|
article
|
| 19 |
Joseph Allen Cook
|
Bagcchi, Sanjeet
|
|
|
22 |
12 |
p. 1677
|
article
|
| 20 |
Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia
|
Bergeron, Anne
|
|
|
22 |
12 |
p. e359-e369
|
article
|
| 21 |
Native mitral valve infective endocarditis caused by Actinobacillus equuli
|
De brauwer, Thomas
|
|
|
22 |
12 |
p. 1770
|
article
|
| 22 |
New boosters are here! Who should receive them and when?
|
Doron, Shira
|
|
|
22 |
12 |
p. 1668-1669
|
article
|
| 23 |
Next-generation malaria subunit vaccines to reduce disease burden in African children
|
Daubenberger, Claudia A
|
|
|
22 |
12 |
p. 1655-1656
|
article
|
| 24 |
Persistence, prevalence, and polymorphism of sequelae after COVID-19 in unvaccinated, young adults of the Swiss Armed Forces: a longitudinal, cohort study (LoCoMo)
|
Deuel, Jeremy Werner
|
|
|
22 |
12 |
p. 1694-1702
|
article
|
| 25 |
Prevention of monkeypox with vaccines: a rapid review
|
Poland, Gregory A
|
|
|
22 |
12 |
p. e349-e358
|
article
|
| 26 |
Radical treatment for blastomycosis following unsuccessful liposomal amphotericin
|
Chew, Christopher
|
|
|
22 |
12 |
p. e377-e381
|
article
|
| 27 |
Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study
|
Wong, Carlos K H
|
|
|
22 |
12 |
p. 1681-1693
|
article
|
| 28 |
Research in brief
|
Devi, Sharmila
|
|
|
22 |
12 |
p. 1676
|
article
|
| 29 |
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation
|
Wang, Qian
|
|
|
22 |
12 |
p. 1666-1668
|
article
|
| 30 |
Suboptimal protection with 3 + 0 PCV13: a need for change?
|
McAlister, Sonia
|
|
|
22 |
12 |
p. 1657-1658
|
article
|
| 31 |
Tackling the politicisation of COVID-19 data reporting through open access data sharing
|
Wells, Chad R
|
|
|
22 |
12 |
p. 1660-1661
|
article
|
| 32 |
The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages
|
Arora, Prerna
|
|
|
22 |
12 |
p. 1665-1666
|
article
|
| 33 |
The global burden of cryptococcosis—a neglected tropical disease?
|
Kabir, Zubair
|
|
|
22 |
12 |
p. 1658-1660
|
article
|
| 34 |
The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis
|
Rajasingham, Radha
|
|
|
22 |
12 |
p. 1748-1755
|
article
|
| 35 |
The Johns Hopkins University Center for Systems Science and Engineering COVID-19 Dashboard: data collection process, challenges faced, and lessons learned
|
Dong, Ensheng
|
|
|
22 |
12 |
p. e370-e376
|
article
|
| 36 |
Time to redefine a primary vaccination series?
|
Tanriover, Mine Durusu
|
|
|
22 |
12 |
p. 1654-1655
|
article
|
| 37 |
Together, apart
|
Sherwood-Martin, Hollie
|
|
|
22 |
12 |
p. 1680
|
article
|
| 38 |
US approval of Tdap vaccine specifically in pregnancy
|
Venkatesan, Priya
|
|
|
22 |
12 |
p. 1671
|
article
|
| 39 |
Waning of antibody levels induced by a 13-valent pneumococcal conjugate vaccine, using a 3 + 0 schedule, within the first year of life among children younger than 5 years in Blantyre, Malawi: an observational, population-level, serosurveillance study
|
Swarthout, Todd D
|
|
|
22 |
12 |
p. 1737-1747
|
article
|
| 40 |
WHO reacts to the spread of Anopheles stephensi
|
Bagcchi, Sanjeet
|
|
|
22 |
12 |
p. 1672
|
article
|
| 41 |
Why hybrid immunity is so triggering
|
The Lancet Infectious Diseases,
|
|
|
22 |
12 |
p. 1649
|
article
|
Journal description